Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The phase 3 SANO trial's 5-year data show that active surveillance after neoadjuvant chemoradiotherapy matches standard esophagectomy in overall survival for esophageal cancer patients who achieve a complete clinical response. While distant metastases were more common in the surveillance group, 43% of those patients avoided surgery entirely. Researchers say the findings support active surveillance as a legitimate option — especially when weighed against surgery's significant complication rates and quality-of-life toll.
For patients with locally advanced esophageal cancer who achieve a complete clinical response after neoadjuvant chemoradiotherapy, skipping immediate surgery may be a viable path. The phase 3 SANO trial — now with 5-year follow-up data presented at ESMO 2026 — found no statistically significant difference in overall survival between active surveillance and standard esophagectomy (50% vs. 54%), reinforcing earlier 2-year noninferiority results.
The catch? Distant metastases were significantly more common in the surveillance group (46% vs. 29%), and esophageal cancer–specific deaths were also higher (40% vs. 30%). Still, 43% of surveillance patients avoided esophagectomy altogether — a meaningful benefit given that ~60% of patients undergoing the surgery experience complications and quality of life suffers considerably.
By the Numbers:
Why it matters: Active surveillance offers a surgery-sparing option with comparable survival for carefully selected patients — but it requires intensive monitoring and should currently be reserved for experienced, high-volume centers. Ongoing trials exploring ctDNA, immunotherapy (nivolumab), and intensified systemic therapy aim to further refine who benefits most.